News Sentiment

LPCN sentiment intelligence

Lipocine Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.41 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+0.8% over one week, +6.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Lipocine Inc. (LPCN) Holds Near Support After Modest Gain, Resistance in Focus - Bull Pennant

Market Reaction

Balanced read

49/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 0.8% Price digesting
Trend fit Trend inactive 6.6% over four weeks
Fair value -43.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 36
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Stock Titan 8
Market source 7
TradingKey 5
Investing.com 4
PR Newswire 3
Investing.com UK 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 19
Regulatory and legal 3
Analyst action 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
Stock Titan Direct company coverage

Lipocine (LPCN) CEO Mahesh Patel receives 52,781 stock options grant

Lipocine Inc. CEO Mahesh V. Patel was granted 52,781 stock options at an exercise price of $2.49 per share as part of his compensation. This grant increases his total reported stock option holdings to 227,214. The options will vest over time, with one-third vesting on June 29, 20

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 00:10
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of Lipocine Inc. – NASDAQ:LPCN

This article provides a brief overview of Lipocine Inc. (NASDAQ: LPCN) focusing on its "Price to book forward" metric. It appears to be a stub or data-centric page from TradingView, lacking detailed financial analysis or news content. The page highlights the stock's market status

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 06:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Lipocine Inc. – NASDAQ:LPCN

This article focuses on the "Price to earnings forward" metric for Lipocine Inc. (NASDAQ: LPCN) as presented on the TradingView platform. It indicates that the specific financial data for this metric is displayed on the detailed company financial page. The content primarily lists

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 18:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Lipocine Inc. – NASDAQ:LPCN

The article discusses the enterprise value to revenue forward of Lipocine Inc. (NASDAQ: LPCN). It is a financial data point available on TradingView, providing an overview of the company's financials, news, and community discussions.

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 03:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Lipocine Inc. – NASDAQ:LPCN

The article "Price to sales forward of Lipocine Inc. – NASDAQ:LPCN" is from TradingView and indicates specific financial data for Lipocine Inc. The main content of the article, which would detail the actual "Price to sales forward" value, is not present in the provided text. The

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 02:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Lipocine Inc. – NASDAQ:LPCN

This article provides financial data for Lipocine Inc. (NASDAQ: LPCN), specifically focusing on its Enterprise Value to EBITDA forward. The content appears to be a basic financial listing from TradingView, indicating no actual data was present in the provided snippet beyond the t

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 23:11
Source
TradingView
TradingView Direct company coverage

Lipocine Inc Actuals & Estimates (NASDAQ:LPCN)

This article provides an overview of Lipocine Inc. (NASDAQ: LPCN) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates for the company, covering income statements, balance sheets, and cash flow, alongside an

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 07:11
Source
TradingView
TradingView Direct company coverage

LPCN Forecast — Price Target — Prediction for 2027

This article provides an overview of Lipocine Inc. (LPCN) stock, including its current price, market capitalization, and recent performance. It also details analysts' price targets, earnings estimates, and upcoming earnings report dates. The article emphasizes that the content is

Tone
Positive 61/100
Event
Earnings
Published
25 Jun 2026 19:10
Source
TradingView
TradingKey Direct company coverage

Lipocine Inc (LPCN) Institutional Confidence

Lipocine Inc (LPCN) has an institutional shareholding score of 3.00, placing it 192nd in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 25.27%, a 35.40% quarterly increase, with James Simons being the largest institutional shareholder.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 00:09
Source
TradingKey
TradingKey Direct company coverage

Lipocine Inc (LPCN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Lipocine Inc (LPCN), detailing its current price momentum score, support and resistance levels for range-bound swing trading. It includes a breakdown of various technical indicators like MACD, RSI, and moving averages, offering buy, s

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 11:41
Source
TradingKey
TradingKey Direct company coverage

Lipocine Inc (LPCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article states that Lipocine Inc (LPCN) has not yet disclosed relevant data regarding its revenue breakdown by business segments, regional revenue, or profit contribution. It provides current stock information for LPCN, including its price, market cap, and daily change.

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 05:41
Source
TradingKey
TradingKey Direct company coverage

Lipocine Inc (LPCN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Lipocine Inc (LPCN) stock, focusing on its dividend history and stock split events. It indicates that the company has not distributed dividends in the past five years and details multiple 17-to-1 reverse stock mergers that occurred on May 11,

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 05:41
Source
TradingKey
TradingKey Direct company coverage

Lipocine Inc (LPCN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Lipocine Inc (LPCN) has an earnings forecast score of 7.00, placing it 313th out of 388 in the Biotechnology & Medical Research industry. Analysts have an average price target of $6.88 for LPCN, with a high of $7.00 and a low of $6.75, recommending a "Buy" trend. The company's ex

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 02:41
Source
TradingKey
Stock Titan Direct company coverage

Lipocine (LPCN) holds virtual KOL event on postpartum depression and LPCN 1154

Lipocine Inc. (LPCN) hosted a virtual Key Opinion Leader (KOL) event on June 12, 2026, focusing on the unmet medical needs in postpartum depression and presenting the clinical profile of its investigational product, LPCN 1154. A detailed slide presentation from the event was file

Tone
Neutral 50/100
Event
Regulatory and legal
Published
12 Jun 2026 19:39
Source
Stock Titan
Finviz Direct company coverage

LPCN - Lipocine Inc Stock Price and Quote

This page provides comprehensive stock information for Lipocine Inc. (LPCN), including its current stock price, financial metrics, analyst ratings, and a chronological list of recent news and insider transactions. Key details include a last close price of $2.39, a market cap of $

Tone
Negative 28/100
Event
Analyst action
Published
05 Jun 2026 16:11
Source
Finviz
Stock Titan Direct company coverage

Lipocine (LPCN) director Higuchi awarded right to buy 1,764 shares at $2.19

Lipocine Inc. director John W. Higuchi has been granted derivative securities allowing him to purchase 1,764 shares of common stock at an exercise price of $2.19 per share. These rights will vest 100% one year from the grant date of June 3, 2026, and will expire on June 3, 2036.

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 19:38
Source
Stock Titan
Stock Titan Direct company coverage

Lipocine (NASDAQ: LPCN) holders back directors and expand stock incentive plan

Lipocine Inc. shareholders approved the Sixth Amended and Restated 2014 Stock and Incentive Plan, expanding the total shares authorized to 1,000,000 and increasing individual award limits. The shareholders also re-elected four directors, ratified Tanner LLC as their independent p

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 19:38
Source
Stock Titan
Stock Titan Direct company coverage

Lipocine (LPCN) director awarded 1,764 stock options at $2.19 exercise price

Lipocine Inc. director Jene Jill M. was granted 1,764 stock options with an exercise price of $2.19 per share, vesting 100% one year from the grant date and expiring on June 3, 2036. This grant is a routine equity compensation to align director incentives with shareholder value,

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 19:38
Source
Stock Titan
Stock Titan Direct company coverage

Director Richard Dana Ono awarded 1,764 Lipocine (LPCN) stock options at $2.19

Lipocine Inc. director Richard Dana Ono was granted 1,764 stock options at an exercise price of $2.19 per share. This equity award is compensation-related and not a direct purchase, with vesting occurring 100% one year from the grant date and an expiration date in 2036. Following

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 19:38
Source
Stock Titan
TradingView Direct company coverage

Lipocine to Host Virtual KOL Event on LPCN 1154 Phase 3 Data for Postpartum Depression

Lipocine will host a virtual Key Opinion Leader (KOL) event on June 12, 2026, to present the Phase 3 topline results and clinical profile of LPCN 1154 for postpartum depression (PPD). The event will discuss the unmet needs in PPD treatment, treatment landscape, and gaps in care,

Tone
Neutral 50/100
Event
Earnings
Published
04 Jun 2026 13:09
Source
TradingView
Market source Direct company coverage

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

Lipocine Inc. is hosting a virtual KOL event on June 12, 2026, to discuss unmet needs in postpartum depression (PPD) and present the clinical profile of LPCN 1154 (BRLIZIO™), their investigational oral brexanolone. The event will feature leading physicians who will review the cur

Tone
Positive 66/100
Event
Regulatory and legal
Published
04 Jun 2026 12:09
Source
Market source
TradingView Direct company coverage

Lipocine presents Phase 3 LPCN 1154 data for postpartum depression at ASCP

Lipocine (LPCN) presented positive Phase 3 clinical data for its investigational drug, LPCN 1154 (oral brexanolone), for postpartum depression at the ASCP Annual Meeting. The results from the placebo-controlled trial, along with a presentation and poster from the meeting, were fu

Tone
Positive 67/100
Event
Regulatory and legal
Published
26 May 2026 21:09
Source
TradingView
Stock Titan Direct company coverage

[8-K] Lipocine Inc. Reports Material Event

Lipocine Inc. filed an 8-K report detailing a scientific presentation rather than a financial event. On May 26, 2026, the company presented positive Phase 3 clinical data for LPCN 1154, an oral brexanolone candidate for treating postpartum depression, at the American Society of C

Tone
Positive 66/100
Event
Market update
Published
26 May 2026 21:09
Source
Stock Titan
Market source Direct company coverage

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

Lipocine Inc. announced that its management will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase on Wednesday, May 20, 2026, at 3:00 PM ET. The biopharmaceutical company, which uses a proprietary technology platform for effective oral drug delivery,

Tone
Positive 61/100
Event
Market update
Published
22 May 2026 03:38
Source
Market source
TradingView Direct company coverage

LPCN: Excluding an outlier site, rapid and durable efficacy with strong safety was demonstrated in PPD

Lipocine Inc. (LPCN) announced positive Phase III results for its postpartum depression (PPD) treatment. The study demonstrated rapid, significant, and durable efficacy with a strong safety profile in key subgroups, especially when an anomalous outlier site was excluded. Sufficie

Tone
Positive 81/100
Event
Earnings
Published
20 May 2026 21:40
Source
TradingView
Investing.com UK Direct company coverage

Lipocine’s postpartum depression drug data to be presented at ASCP

Lipocine Inc. will present Phase 3 clinical data for its postpartum depression drug, LPCN 1154, at the American Society of Clinical Psychopharmacology Annual Meeting from May 26-29. Despite a significant stock decline and the failure of LPCN 1154 to meet its primary endpoint in a

Tone
Negative 40/100
Event
Market update
Published
19 May 2026 15:10
Source
Investing.com UK